Abstract: Objective To explore the effects of sulforaphane on Toll-like receptor 4 (TLR4)/ myeloid differentiation factor 88 (MyD88) pathway and its downstream inflammatory cytokines in patients with chronic obstructive pulmonary disease (COPD).Methods From Jan.2012 to Mar.2013,thirty-two stable COPD patients and thirty healthy donors (non-COPD group) from the First Hospital of Lanzhou University were recruited.The peripheral blood monocytes were isolated and induced to macrophages (monocyte-derived macrophages,MDMs).The MDMs of COPD patients were divided into a blank control group,a LPS group,a sulforaphane group,a sulforaphane and LPS group (combined group),while the MDMs from the non-COPD group received no drug intervention.The number of cells in each group was 3 ×106.The mRNA and protein expression of TLR4 and MyD88 were measured with real-time PCR and Western blot.The TNF-α and IL-6 levels in the culture supernatant were measured with ELISA.Oneway ANOVA and LSD-t test were used for statistical analysis.Results The levels of mRNA and protein of TLR4 and MyD88 and the contents of TNF-α and IL-6 in the culture supernatant were higher in the blank control group [3.7 ±0.5,1.9±0.4,0.45 ±0.18,1.11 ±0.65,(31 ±4) and (43 ±5) μg/L] than those in the nonCOPDgroup [1.00,1.00,0.26±0.14,0.58±0.40,(19±2) and (29±4) μg/L] (t=2.19-12.11,P <0.05 or P <0.01).After LPS treatment (LPS group),the above parameters [5.5 ± 1.1,3.4 ± 1.6,0.65 ± 0.20,1.66 ± 0.64,(47 ± 4) and (54 ± 5) μg/L] were increased as compared to those in the blank control group (t =2.39-11.9,P < 0.05 or P < 0.01),but after sulforaphane treatment (Sulforaphane group),these parameters [2.2 ± 0.4,1.0 ± 0.6,0.25 ± 0.09,0.62 ± 0.34,(20 ± 3) and (27 ±4) μg/L] were decreased as compared to those in the blank control group (t =2.13-8.46,P < 0.05 or P < 0.01).Similarly,these parameters in the combined group [3.2 ± 0.5,1.5 ± 0.8,0.33 ± 0.11,0.77 ±0.25,(31 ±3) and (33 ±4) μg/L] were also remarkably decreased as compared to those in the LPS group (t =3.87-12.24,all P<0.01).Conclusions The TLR4/MyD88 pathway was activated and its downstream inflammatory cytokines were increased in macrophages from COPD patients.Sulforaphane could inhibit the TLR4/MyD88 pathway and reduce the releasing of downstream inflammatory cytokines,suggesting that sulforaphane may have an anti-inflammatory effect in COPD.